--(www.USEquityNews.com)-- 05/21/2008 - Healthcare industry alert provided by U.S. Equity News. Shares of Obagi Medical Products Inc. (NASDAQ: OMPI) rose after an analyst placed a "Buy" rating on the stock, saying new products will help the skin-care products maker post stronger profit growth. Roth Capital Partners analyst Greg Gust began coverage with a "Buy" rating and a price target of $14 per share, implying growth of 79 percent over its closing price Monday of $7.82. Gust said weakness in the U.S. economy is hurting Obagi's aesthetic products business, but as the company introduces new product lines, revenue growth could increase.
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) recently announced that data on NEBIDO(R) (testosterone undecanoate), an investigational, long-acting intramuscular injection for the treatment of hypogonadism, was presented in a late breaker presentation at the 2008 American Urological Association Annual Meeting held in Orlando. The data, which had been previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated with NEBIDO for 24 weeks. This study demonstrated that 94 percent of the men had their testosterone levels restored and maintained to within normal levels; further, 92 percent of these men expressed satisfaction with their NEBIDO treatment. Sixty-two percent of men participating in the Phase III study had previously used other testosterone treatments.
Vista Partners announced recently that it has initiated coverage on Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE). Ross Silver, Director of Research of Vista Partners stated, "Alseres' recombinant-protein-based drug named Cethrin has shown highly encouraging clinical and preclinical data to date. Cethrin would serve a multi-billion dollar market if approved. In addition to Cethrin, Alseres has a molecular imaging program in Phase III clinical trials, a program we believe will likely be partnered within the next 12 months. Alseres is a highly attractive investment at its current valuation." To download a free copy of the report, please visit the Vista Partners website, http://www.vistap.com and click on the download research icon.
TapImmune Inc. (OTCBB: TPIM) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development program includes phased manufacturing and production for both infectious disease adjuvant and cancer therapeutic vaccine candidates. These will culminate in toxicology studies and will coincide with pre-IND meeting preparation with the FDA and clinical protocols for our proposed phase 1 human studies. This milestone is predicated on the back of a year where we have seen the completion of the UBC assignment agreement finally effecting our acquisition of the core technologies we developed under the world-wide license agreement.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
